Kazia Therapeutics Limited

🎗️ It’s DIPG Awareness Day! At Kazia Therapeutics Limited, we’re deeply committed to the fight against DIPG, an aggressive childhood #braincancer.   The most common malignancy in children, brain cancer counts for approximately one-third of childhood cancer deaths and effective treatment remains a very high unmet medical need.    We want to acknowledge Prof Matt Dun and his team of researchers from the University of Newcastle, who are dedicated to finding new therapies to treat DIPG.   If you’d like to learn more or donate to Prof Dunn’s foundation, please visit the RUN DIPG charity here: https://rundipg.org   #childhoodbraincancer #braincancertreatment #KZIA

We are excited to share an interview with Professor Sudha Rao from QIMR Berghofer Medical Research Institute, which discusses the cutting-edge developments being made by her team in #breastcancer therapeutics.    In this interview, Professor Rao offers insights into #epigenetic science and how they have “identified a novel PI3K epigenetic switch”. She further describes the preclinical research to date as “a game changer; I believe because our data is showing its utility in being able to reinvigorate patient’s immune system.”  Professor Rao discusses the potential of immunotherapy combinations with #paxalisib as a novel approach to treating advanced breast cancer, and what’s next for her research.   Watch the interview here: https://lnkd.in/dM7kQTSJ

Kazia Therapeutics Limited is pleased to announce the completion of stage 1 of our Phase 1 clinical trial for our drug candidate, EVT801, in advanced cancer patients.   Upon reviewing all preliminary safety and pharmacokinetic (PK) data, the Safety Review Team has concluded unanimously that the primary and secondary objectives of the stage 1 trial have been successfully met.    A total of 26 cancer patients received EVT801 across six dosing cohorts. Eleven types of cancer, with advanced ovarian cancer being the most prevalent (11 patients), were enrolled in this study.    Dr John Friend, CEO of Kazia Therapeutics, said: “The signals of clinical activity, especially in patients with advanced ovarian cancer are highly encouraging as we continue to progress the clinical development program for EVT801 as a potential first-in-class VEGFR3 inhibitor. With a median survival time of less than 4 years, there is a large unmet need for new therapies in patients with high-grade serous ovarian cancer."   Final stage 1 data and next development steps will be presented at an upcoming scientific conference in H2 2024.   For further details, please visit: LINK TO WEBSITE.   #oncologydrug #EVT801

Did you know brain tumours kill more children and adults under 40 than any other cancer? May is #BrainTumourAwarenessMonth which is aimed at raising awareness of brain tumours, supporting patients and their families, and driving funding for further research. Learn more here https://shorturl.at/fjBP4 (in US) or here https://shorturl.at/eILU9 (in Australia).

Kazia Therapeutics Limited is pleased to release an updated corporate presentation, containing details of the research development of our two lead drugs #paxalisib and EVT-801.   Our GBM, paediatric and brain metastasis development programs for paxalisib remain a key focus, as does advancing paxalisib’s development in other key oncology indications. Stage one of the EVT-801 Phase 1 clinical study has demonstrated encouraging initial results, and is expected to conclude 2024.   To access the full presentation, please visit: https://lnkd.in/g79HE5n8

It has been a busy time for Kazia Therapeutics Limited at this week’s 2024 Annual Meeting of the American Association of Cancer Research (AACR) in California, with three presentations over the past few days.   CEO Dr John Friend joined Dr Carlos Gomez-Roca, MD, PhDs, principal investigator and Dr Pierre Fons, VP Translational Biomarkers at Evotec, who presented data from the phase 1 study of EVT801 in advanced solid tumours. The data presented outlined initial clinical data from the study and underpins the direction for the next stage of the study. Preclinical study results of a combination therapy of paxalisib and gemcitabine in patients with relapsed/recurrent AT/RT were presented in a mini-symposium. Based on the promising findings, The Pacific Pediatric Neuro-Oncology Consortium (PNOC) is planning to include this combination therapy in the next international clinical trial for patients with relapsed/recurrent AT/RT.   Kazia’s AACR abstracts are available via these links: https://lnkd.in/g-DveJtk https://lnkd.in/gVM5Jdwn https://lnkd.in/gK34MM4W

Today is World Health Day and Kazia Therapeutics Limited stands united with the global community, echoing this year's theme, 'My health, my right'.  As we tackle formidable cancers such as rare forms of brain tumours, this year's #WorldHealthDay message is an important reminder for us to keep going. Through pioneering research and international collaboration, we aim to bring cutting-edge treatments to those who need it most.   Discover more about World Health Day on World Health Organization’s website here: https://shorturl.at/mvwxK  

Kazia is pleased to announce that we have entered into an exclusive licensing agreement with Sovargen, a biotechnology company specialising in central nervous system (CNS) diseases, to develop, manufacture and commercialise paxalisib as a potential treatment of intractable #epilepsy in focal cortical dysplasia type 2 (FCD T2) and tuberous sclerosis complex (TSC) disease. Kazia CEO Dr. John Friend said: “Kazia’s primary focus of paxalisib continues to be oncology, with multiple studies ongoing. Our license with Sovargen provides us the ability to explore the impact of paxalisib outside of our area of expertise where there is substantial patient need and market opportunity. We are enthusiastic about seeing paxalisib’s potential explored in these patient populations.” For further information, please refer to our announcement here: https://shorturl.at/uyCDQ

A detailed update from Kazia Therapeutics Limited on their EVT801 #oncology drug has just been released, providing further insight into the drug's unique mode of action and an update on its clinical development program. Presentation link in the post below.

Kazia Therapeutics Limited is pleased to release a new presentation detailing the opportunities for our EVT801 #oncology asset. The presentation highlights how EVT801 works and its unique points of difference over other #angiogenesis drugs currently on the market. It also provides an update on our Phase 1 clinical study, through which 32 patients have been included, with 26 patients treated across 5 dosing cohorts. Patients are currently being enrolled in the first stage of the study, and further next steps for the clinical development program are outlined. You can access the full presentation here: https://shorturl.at/wEKUZ